Literature DB >> 27278166

The efficacy of cibenzoline for reducing the left ventricular pressure gradient of hypertrophic obstructive cardiomyopathy: A case report.

Hideki Igarashi1.   

Abstract

A 46 year-old man with hypertrophic obstructive cardiomyopathy (HOCM) was referred to this clinic complaining of shortness of breath. His symptoms remained even after he had been treated with bisoprolol, lisinopril, and verapamil. We started treating him with cibenzoline, instead of verapamil. Continuous-wave Doppler examination revealed a marked decrease from 95.9 mm Hg to 8.8 mmHg in the left ventricular outflow tract pressure gradient after administration of cibenzoline, and the symptom disappeared. The electrical axis of the electrocardiogram deviated from +53 to +95 degrees, and the QRS interval was increased from 0.095 to 0.114 seconds. By the M-mode echocardiogram, the interventricular septum was observed moved paradoxically in the early, systolic phase. We suggest the possibility that cibenzoline modifies intraventricular conduction and causes asynchronous contraction of the left ventricle, resulting in decrease in the left ventricular outflow tract pressure gradient.

Entities:  

Keywords:  HOCM; cibenzoline

Year:  2003        PMID: 27278166     DOI: 10.1007/BF02481371

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  10 in total

1.  Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.

Authors:  M Hamada; Y Shigematsu; S Ikeda; Y Hara; H Okayama; K Kodama; T Ochi; K Hiwada
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

2.  Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy.

Authors:  M H Schönbeck; H P Brunner-La Rocca; P R Vogt; M L Lachat; R Jenni; O M Hess; M I Turina
Journal:  Ann Thorac Surg       Date:  1998-05       Impact factor: 4.330

3.  Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial.

Authors:  R A Nishimura; J M Trusty; D L Hayes; D M Ilstrup; D R Larson; S N Hayes; T G Allison; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1997-02       Impact factor: 24.094

4.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.

Authors:  H Seggewiss; U Gleichmann; L Faber; D Fassbender; H K Schmidt; S Strick
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

5.  Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up in 185 patients.

Authors:  Z Krajcer; R D Leachman; D A Cooley; R Coronado
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

6.  Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy.

Authors:  M Hamada; Y Shigematsu; Y Hara; M Suzuki; T Ohtsuka; G Hiasa; A Ogimoto; H Saeki; J Suzuki; K Hiwada
Journal:  Jpn Circ J       Date:  2001-06

7.  Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide.

Authors:  C Pollick
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

8.  Effect of cibenzoline, a class ia antiarrhythmic agent, on left ventricular diastolic function in hypertrophic cardiomyopathy.

Authors:  I Kondo; K Mizushige; S Nozaki; Y Iwado; H Masugata; M Kohno; H Matsuo
Journal:  Cardiovasc Drugs Ther       Date:  2001-09       Impact factor: 3.727

9.  Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia.

Authors:  J S Millar; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-03       Impact factor: 8.739

10.  Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy.

Authors:  X Jeanrenaud; J J Goy; L Kappenberger
Journal:  Lancet       Date:  1992-05-30       Impact factor: 79.321

  10 in total
  1 in total

Review 1.  Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.

Authors:  Chiara Palandri; Lorenzo Santini; Alessia Argirò; Francesca Margara; Ruben Doste; Alfonso Bueno-Orovio; Iacopo Olivotto; Raffaele Coppini
Journal:  Drugs       Date:  2022-06-13       Impact factor: 11.431

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.